Sonnet Net Income from 2010 to 2025

SONN Stock  USD 1.52  0.02  1.33%   
Sonnet Biotherapeutics Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -5.3 M. During the period from 2010 to 2025, Sonnet Biotherapeutics Net Loss quarterly data regression pattern had sample variance of 67 T and median of (6,403,371). View All Fundamentals
 
Net Loss  
First Reported
2006-09-30
Previous Quarter
-3.1 M
Current Value
-3.2 M
Quarterly Volatility
2.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sonnet Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonnet Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 2.4 M or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 2.24, Dividend Yield of 0.0 or PTB Ratio of 9.27. Sonnet financial statements analysis is a perfect complement when working with Sonnet Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors.

Latest Sonnet Biotherapeutics' Net Income Growth Pattern

Below is the plot of the Net Income of Sonnet Biotherapeutics Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Sonnet Biotherapeutics financial statement analysis. It represents the amount of money remaining after all of Sonnet Biotherapeutics Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Sonnet Biotherapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sonnet Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (7.44 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Sonnet Net Income Regression Statistics

Arithmetic Mean(9,364,714)
Geometric Mean6,617,889
Coefficient Of Variation(87.37)
Mean Deviation6,036,334
Median(6,403,371)
Standard Deviation8,182,377
Sample Variance67T
Range28.8M
R-Value(0.40)
Mean Square Error60.3T
R-Squared0.16
Significance0.13
Slope(687,012)
Total Sum of Squares1004.3T

Sonnet Net Income History

2025-5.3 M
2023-7.4 M
2022-18.8 M
2021-29.8 M
2020-25 M
2019-5 M

Other Fundumenentals of Sonnet Biotherapeutics

Sonnet Biotherapeutics Net Income component correlations

About Sonnet Biotherapeutics Financial Statements

Sonnet Biotherapeutics investors utilize fundamental indicators, such as Net Income, to predict how Sonnet Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-4.9 M-5.1 M
Net Loss-17.4 M-18.3 M
Net Loss-16.1 M-16.9 M
Net Loss-15.6 K-16.4 K
Net Income Per E B T 0.76  0.87 
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.59)
Revenue Per Share
0.959
Quarterly Revenue Growth
52.688
Return On Assets
(1.34)
Return On Equity
(2.85)
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.